Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 4/2014

01-04-2014 | Original Contributions

Gastric Bypass Surgery May Improve Beta Cell Apoptosis with Ghrelin Overexpression in Patients with BMI ≥ 32.5 kg/m2

Authors: Jian Yang, Xiao Feng, Shuzhe Zhong, Yong Wang, Jingang Liu

Published in: Obesity Surgery | Issue 4/2014

Login to get access

Abstract

Background

Roux-en-Y gastric bypass (RYGB) surgery can lead to long-term remission of type 2 diabetes mellitus, depending on changes in weight and circulating levels of gut hormones. The general objectives of this study were to evaluate changes in plasma levels of the ghrelin gene products following RYGB surgery and to determine the role of ghrelin in inhibiting apoptosis of INS-1 cells induced by hyperglycemia.

Methods

Sixteen obese Chinese patients with type 2 diabetes mellitus who underwent gastric bypass surgery were assessed in this investigation. Blood plasma levels of acylated ghrelin (AG), unacylated ghrelin (UAG), and obestatin (OB) were measured both before and 12 months after RYGB surgery. To determine the effect of ghrelin on inhibition of apoptosis, INS-1 cells were cultured in a high glucose concentration and treated with AG, UAG, or OB. Cell viability was assessed using the MTT assay, and apoptosis was evaluated by flow cytometry with Annexin-V FITC/PI double staining and transmission electron microscopy. Intracellular calcium trafficking was assessed using flow cytometry and confocal microscopy. All the data was processed using the SPSS statistical package and expressed as means ± SD, with p < 0.05 considered statistically significant.

Results

Fasting and postprandial plasma levels of AG, UAG, and OB were significantly elevated 1 year after RYGB surgery. Mean fasting plasma AG, UAG, and OB increased from preoperative levels of 37.0, 462, and 69.4 pg/mL, respectively, to 61.4, 804, and 112 pg/mL (with p < 0.05) 1 year after surgery. Mean 120-min postprandial plasma AG, UAG, and OB increased from preoperative levels of 23.8, 287, and 53.8 pg/mL, respectively, to 39.7, 516, and 69.0 pg/mL (with p < 0.05) postoperatively. After a 1-week culture of INS-1 beta cell in high glucose, peptide treatment showed increased cell survival by 69 % (AG), 60 % (UAG), and 73 % (OB) and decreased apoptosis by 49 % (AG), 37 % (UAG), and 38 % (OB) compared to cells cultured in high glucose without peptides, respectively (with p < 0.05). Treatment with AG, UAG, and OB inhibited intracellular calcium mobilization and intramitochondrial calcium accumulation in INS-1 cells to protect the cells from hyperglycemia-induced apoptosis.

Conclusions

The remission of diabetes following RYGB surgery seems to be associated with increased plasma levels of AG, UAG, and OB. Moreover, the ghrelin gene products probably protect β cells by maintaining calcium homeostasis. Additional mechanisms, currently unclear, are likely to be involved as well.
Literature
1.
2.
Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.PubMedCrossRef
3.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248.e5–56.e5.CrossRef
4.
Buchwald H, Avidor Y, Braunwald E, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef
5.
Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. J Diabetes Care. 2008;31(2):$290–96.CrossRef
6.
7.
Shak JR, Roper J, Perez-Perez GI, et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg. 2008;18:1089–96.PubMedCentralPubMedCrossRef
8.
Martins C, Kjelstrup L, Ingrid L, et al. Impact of sustained weight loss achieved through Roux-en-Y gastric bypass or a lifestyle intervention on ghrelin, obestatin, and ghrelin/obestatin ratio in morbidly obese patients. Obes Surg. 2011;21(6):751–8.PubMedCrossRef
9.
Holdstock C, Engstrӧm BE, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab. 2003;88:3177–83.PubMedCrossRef
10.
Faraj M, Havel PJ, Phélis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594–602.PubMedCrossRef
11.
Fruhbeck G, Rotellar F, Hernández-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 2004;14:1208–15.PubMedCrossRef
12.
Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623–30.PubMedCrossRef
13.
Morinigo R, Casamitjana R, Moize V, et al. Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res. 2004;12:1108–16.PubMedCrossRef
14.
Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.PubMedCrossRef
15.
Abizaid A, Horvath TL. Ghrelin and the central regulation of feeding and energy balance. Indian J Endocrinol Metab. 2012;16 Suppl 3:S617–26.PubMedCentralPubMed
16.
González-Jiménez E, Schmidt Río-Valle J. Regulation of dietary intake and energy balance: factors and mechanisms involved. Nutr Hosp. 2012;27(6):1850–9.PubMed
17.
Damjanovic SS, Lalic NM, Pesko PM, et al. Acute effects of ghrelin on insulin secretion and glucose disposal rate in gastrectomized patients. J Clin Endocrinol Metab. 2006;91(7):2574–81.PubMedCrossRef
18.
Kim SW, Kim KW, Shin CS, et al. Acylated ghrelin secretion is acutely suppressed by oral glucose load or insulin-induced hypoglycemia independently of basal growth hormone secretion in humans. Horm Res. 2007;67(5):211–9.PubMedCrossRef
19.
Kishimoto I, Tokudome T, Hosoda H, et al. Ghrelin and cardiovascular diseases. J Cardiol. 2012;59(1):8–13.PubMedCrossRef
20.
Korbonits M, Goldstone AP, Gueorguiev M, et al. Ghrelin—a hormone with multiple functions. Front Neuroendocrinol. 2004;25(1):27–68.PubMedCrossRef
21.
Soares JB, Leite-Moreira AF. Ghrelin, des-acyl ghrelin and obestatin: three pieces of the same puzzle. Peptides. 2008;29(7):1255–70.PubMedCrossRef
22.
Granata R, Baragli A, Settanni F, et al. Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol. 2010;45(3):107–18.PubMedCrossRef
23.
Granata R, Isgaard J, Alloatti G, et al. Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp Biol Med (Maywood). 2011;236(5):505–14.CrossRef
24.
Holst B, Egerod KJ, et al. G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction. Endocrinology. 2009;150(6):2577–85.PubMedCentralPubMedCrossRef
25.
Fujimiya M, Asakawa A, Ataka K, et al. Ghrelin, des-acyl ghrelin, and obestatin: regulatory roles on the gastrointestinal motility. Int J Pept. 2010;2010:305192.PubMedCentralPubMed
26.
Chanclón B, Luque RM, Córdoba-Chacón J, et al. Role of endogenous cortistatin in the regulation of ghrelin system expression at pancreatic level under normal and obese conditions. PLoS One. 2013;8(2):e57834.PubMedCentralPubMedCrossRef
27.
Salehi A, Dornonville de la Cour C, Håkanson R, et al. Effects of ghrelin on insulin and glucagon secretion: a study of isolated pancreatic islets and intact mice. Regul Pept. 2004;118(3):143–50.PubMedCrossRef
28.
Peng Z, Xiaolei Z, Al-Sanaban H, et al. Ghrelin inhibits insulin release by regulating the expression of inwardly rectifying potassium channel 6.2 in islets. Am J Med Sci. 2012;343(3):215–9.PubMedCrossRef
29.
Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond). 2009;33 Suppl 1:S33–40.CrossRef
30.
Merglen A, Theander S, Rubi B, et al. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology. 2004;145:667–78.PubMedCrossRef
31.
Asfari M, Janjic D, Meda P, et al. Establishment of 2-mercaptoethanol dependent differentiated insulin-secreting cell lines. Endocrinology. 1992;130:167–78.PubMed
32.
33.
Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613–9.PubMedCentralPubMedCrossRef
34.
Hideharu S, Poochong T, Schauer PR, et al. Review of metabolic surgery for type 2 diabetes in patients with a BMI < 35 kg/m2. J Obes. 2012;2012:147256.
35.
Schernthaner G, Brix JM, Kopp HP, et al. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. Diabetes Care. 2011;34 Suppl 2:S355–60.PubMedCentralPubMedCrossRef
36.
Oliván B, Teixeira J, Bose M, et al. Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg. 2009;249(6):948–53.PubMedCentralPubMedCrossRef
37.
Kelishadi R, Hashemipour M, Mohammadifard N, et al. Short- and long-term relationships of serum ghrelin with changes in body composition and the metabolic syndrome in prepubescent obese children following two different weight loss programmes. Clin Endocrinol. 2008;69(5):721–9.CrossRef
38.
Fruhbeck G, Diez-Caballero A, Gil M, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg. 2004;14:606–12.PubMedCrossRef
39.
Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86:4753–8.PubMedCrossRef
40.
41.
Akamizu T, Kangawa K. The physiological significance and potential clinical applications of ghrelin. Eur J Intern Med. 2012;23:197–202.PubMedCrossRef
42.
43.
Patriti A, Facchiano E, Gullà N, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2007;245(1):157–8.PubMedCentralPubMedCrossRef
44.
Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93(2):210–5.PubMedCrossRef
45.
46.
Wiedmer P, Nogueiras R, Broglio F, et al. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3(10):705–12. Review.PubMedCrossRef
47.
Favaro E, Granata R, Miceli I, et al. The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia. 2012;55(4):1058–70.PubMedCentralPubMedCrossRef
48.
Wang W, Zhang D, Zhao H, et al. Ghrelin inhibits cell apoptosis induced by lipotoxicity in pancreatic beta-cell line. Regul Pept. 2010;161(1–3):43–50.PubMedCrossRef
49.
Cai L, Li W, Wang G, et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome c-mediated caspase-3 activation pathway. Diabetes. 2002;51:1938–48.PubMedCrossRef
50.
Wold LE, Ceylan-Isik AF, Fang CX, et al. Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med. 2006;40:1419–29.PubMedCrossRef
51.
Li J, Wang P, Yu S, et al. Calcium entry mediates hyperglycemia-induced apoptosis through Ca2+/calmodulin-dependent kinase II in retinal capillary endothelial cells. Mol Vis. 2012;18:2371–9.PubMedCentralPubMed
52.
Müller I, Lipp P, Thiel G. Ca2+ signaling and gene transcription in glucose-stimulated insulinoma cells. Cell Calcium. 2012;52(2):137–51.PubMedCrossRef
53.
Younce CW, Burmeister MA, Ayala JE. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol. 2013;304(6):C508–18.PubMedCrossRef
54.
Herchuelz A, Nguidjoe E, Jiang L, et al. β-Cell preservation and regeneration in diabetes by modulation of β-cell Ca2+ homeostasis. Diabetes Obes Metab. 2012;14(3):136–42.PubMedCrossRef
55.
56.
57.
Rudijanto A. Calcium channel blocker (diltiazem) inhibits apoptosis of vascular smooth muscle cell exposed to high glucose concentration through lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) pathway. Acta Med Indones. 2010;42(2):59–65.PubMed
58.
Wang Y, Gao L, Li Y, Sun Z, et al. Nifedipine protects INS-1 β-cell from high glucose-induced ER stress and apoptosis. Int J Mol Sci. 2011;12(11):7569–80.PubMedCentralPubMedCrossRef
59.
60.
Giorgi C, Agnoletto C, Bononi A, et al. Mitochondrial calcium homeostasis as potential target for mitochondrial medicine. Mitochondrion. 2012;12(1):77–85.PubMedCentralPubMedCrossRef
61.
Wang Y, Nishi M, Doi A, et al. Ghrelin inhibits insulin secretion through the AMPK–UCP2 pathway in beta cells. FEBS Lett. 2010;584(8):1503–8.PubMedCrossRef
62.
Buschard K, Hy M, Bokvist K, et al. Sulfatide controls insulin secretion by modulation of ATP-sensitive K(+)-channel activity and Ca(2+)-dependent exocytosis in rat pancreatic beta-cells. Diabetes. 2002;51:2514–21.PubMedCrossRef
63.
Zhang CY, Baffy G, Perret P, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2001;105:745–55.PubMedCrossRef
64.
Lee SH, Lee HY, Kim SY, et al. Enhancing effect of taurine on glucose response in UCP2-overexpressing beta cells. Diabetes Res Clin Pract. 2004;66 Suppl 1:S69–74.PubMed
65.
Ma X, Lin Y, Lin L, et al. Ablation of ghrelin receptor in leptin-deficient ob/ob mice has paradoxical effects on glucose homeostasis when compared with ablation of ghrelin in ob/ob mice. Am J Physiol Endocrinol Metab. 2012;303(3):E422–31.PubMedCentralPubMedCrossRef
Metadata
Title
Gastric Bypass Surgery May Improve Beta Cell Apoptosis with Ghrelin Overexpression in Patients with BMI ≥ 32.5 kg/m2
Authors
Jian Yang
Xiao Feng
Shuzhe Zhong
Yong Wang
Jingang Liu
Publication date
01-04-2014
Publisher
Springer US
Published in
Obesity Surgery / Issue 4/2014
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-013-1135-4

Other articles of this Issue 4/2014

Obesity Surgery 4/2014 Go to the issue

Original Contributions

Serum SPARC and Matrix Metalloproteinase-2 and Metalloproteinase-9 Concentrations after Bariatric Surgery in Obese Adults

Original Contributions

Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Patients with Type 2 Diabetes Mellitus

Original Contributions

Effect of Laparoscopic Roux-en-Y gastric Bypass on Body Composition and Insulin Resistance in Chinese Patients with Type 2 Diabetes Mellitus

Original Contributions

Esophageal Dysmotility After Laparoscopic Gastric Band Surgery

Letter to Editor/LED Reply

Reply to “Still Controversies After Mini Gastric Bypass”

Other

Is It Time to Lower the Bar for Bariatric Surgery?